MAZE: HORIZON phase II data for AMKD shows strong efficacy, with pivotal trials and PKU advances ahead
Three clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and a pivotal trial planned. Initial results show strong efficacy across patient subgroups, and biomarker strategies are being explored. The PKU program is also progressing with promising early data.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.